Stratistics MRC에 따르면 세계의 CT/NG 검사 시장은 2025년 21억 6,000만 달러를 차지하고, 예측 기간 중 CAGR은 10.6%로 성장해, 2032년까지 43억 8,000만 달러에 달할 것으로 예측되고 있습니다.
CT/NG 검사란 세계에서 가장 흔한 성감염증(STI)인 클라미디아 트라코마티스(CT)와 임균(NG)을 검출하기 위한 진단검사를 가리킵니다. 검사는 조기 진단과 치료에 필수적입니다. 일반적으로 CT/NG 검사에는 핵산 증폭 검사(NAAT)가 사용되며 소변 검체, 질 면봉 및 기타 검체를 사용하여 실시 할 수 있으며 높은 감도와 특이성을 가지고 있습니다.
미국 질병 예방관리센터(CDC)에 따르면 2023년에는 미국에서 240만 건이 넘는 클라미디아, 임병, 매독의 사례가 보고되었습니다.
STI 유병률 증가
CT/NG 검사 시장을 추진하는 주요 요인 중 하나는 클라미디아와 임병의 세계의 이환율이 상승하는 것입니다. 세계보건기구(WHO)에 따르면, 클라미디아와 임병은 세계에서 매년 새롭게 발생하는 치유 가능한 STI 감염증 3억 7,400만 건의 상당 부분을 차지하고 있습니다.
비싼 고도 진단 검사
핵산 증폭 검사(NAAT)와 같은 고도의 진단 기술은 그 감도와 특이도가 높음에도 불구하고 비용이 높기 때문에 특히 저소득 및 중소득국가에서는 접근이 제한될 가능성이 있습니다. 특히 STI 검사의 자금이 부족한 지역에서는 이러한 경제적인 장해가 보급을 방해하고 있습니다. 또한, 특히 보험에 가입하지 않은 사람들이나 공적 헬스케어 제도가 없는 지역에서는 자기 부담액이 정기적으로 검사를 받는 의욕을 잃게 할 수도 있습니다.
원격 의료와 디지털 건강의 통합
원격 의료 플랫폼과 디지털 헬스 솔루션의 활용 확대로 CT/NG 검사에 새로운 길을 열어가고 있습니다. 보다 좋은 데이터 수집과 접촉자 추적도 디지털 헬스 툴에 의해 가능하게 되어, 공중 위생 서베이란스를 서포트합니다. 또한 COVID-19의 대유행이 이 동향을 가속시켜, 환자와 의료 제공업체 양쪽이 가상 케어를 보다 안심하고 이용할 수 있게 되어 있는 것을 증명하고 있도록, 진단 기업은 검사를 디지털
저자원 환경에서 신드로믹 관리와의 경쟁
자금 부족과 검사 기관에 대한 접근 부족으로 인해 STI의 신드로믹 관리는 많은 개발 도상국에서 여전히 널리 사용되고 있습니다. 또한 진단이 가장 필요한 고부담국에서는 포인트 오브 케어 검사가 보다 이용하기 쉬워져 현행 절차에 포함되지 않는 한 진단의 도입은 제한된 채로 있을 가능성이 있습니다.
COVID-19 팬데믹은 CT/NG 검사 시장에 다양한 영향을 미쳤습니다. 처음에는 공급망의 혼란, 건강 관리 시스템에 대한 과도한 부담, 검사 자원의 SARS-CoV-2 진단에 대한 재배포로 검사 서비스가 중단되었습니다. STI의 정기 검진 프로그램이 중단되거나 축소된 결과, 검사 수는 일시적으로 감소하고 진단도 늦어졌습니다.
분석 및 키트 분야는 예측 기간 동안 최대가 될 전망
분석 및 키트 분야는 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 이에 적합하기 때문에 임상 실험실, 병원, 심지어 가정용 검사 키트에서도 자주 사용됩니다. 또한, 분석 기반 솔루션은 특히 증상이 없는 환자에서 조기 및 정확한 진단의 필요성이 증가함에 따라 점점 더 널리 사용되고 있습니다.
예측 기간 동안 CAGR이 가장 높을 것으로 예상되는 것은 재택 케어 분야
예측 기간 동안 가장 높은 성장률을 보여줄 것으로 예상되는 것은 재택 케어 설정 분야입니다. 의료기관을 방문하지 않고 인증 실험실에 샘플 송부 및 자체 검사를 가능하게 함으로써, 이러한 솔루션은 검사 빈도를 향상시켜 스티그마를 경감합니다.
예측 기간 동안 아시아태평양이 가장 큰 시장 점유율을 차지할 것으로 예상되며, 이는 주로 이 지역의 인구 규모, STI 감염률의 상승, 성적 건강 의식 증가에 의한 것입니다. 인프라의 확대, STI 스크리닝 프로그램을 지원하는 정부의 이니셔티브에 의한 점이 큽니다.
예측 기간 동안 북미는 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 이는 견고한 건강 관리 시스템, 성병에 대한 높은 지식, 최첨단 진단 도구의 광범위한 사용으로 인한 것입니다. 또한, 북미 CT/NG 검사 시장의 강력한 성장을 지지하는 변수로서, 고감도 한편 신속한 검사 기술의 이용 가능성, 성적 건강 프로그램에 대한 공공 및 민간 투자 증가 등을 들 수 있습니다.
According to Stratistics MRC, the Global CT/NG Testing Market is accounted for $2.16 billion in 2025 and is expected to reach $4.38 billion by 2032 growing at a CAGR of 10.6% during the forecast period. CT/NG testing refers to diagnostic tests used to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), two of the most common sexually transmitted infections (STIs) worldwide. These tests are essential for early diagnosis and treatment because, although both infections frequently show no symptoms, if treatment is not received, they can cause major health problems like pelvic inflammatory disease and infertility. Typically, CT/NG testing uses nucleic acid amplification tests (NAATs), which can be carried out with urine samples, vaginal swabs, or other specimen types and have high sensitivity and specificity. Regular screening is a crucial public health tactic to stop the spread of these infections, particularly among sexually active people.
According to the Centers for Disease Control and Prevention (CDC), over 2.4 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2023. Chlamydia accounted for more than 1.6 million cases, making it the most commonly reported sexually transmitted infection (STI).
Growing STI prevalence
One of the major factors propelling the CT/NG testing market is the rising global incidence of chlamydia and gonorrhea. Over 700,000 cases of gonorrhea and over 1.6 million cases of chlamydia were reported in the United States in 2021 alone, according to the CDC. Because asymptomatic infections often go undiagnosed, these figures are probably underestimates. According to the World Health Organization (WHO), Chlamydia and gonorrhea account for a significant portion of the 374 million new curable STI infections that occur worldwide each year. In order to stop the disease from spreading further and to start treatment as soon as possible, diagnostic testing has increased dramatically as a result of this high disease burden.
Expensive advanced diagnostic testing
The high cost of advanced diagnostic technologies, like nucleic acid amplification tests (NAATs), can restrict access, particularly in low- and middle-income nations, despite their high sensitivity and specificity. Underfunded public health systems or smaller clinics may not be able to afford the costly reagents, specialized equipment, and skilled personnel needed for these tests. Widespread adoption is hampered by this financial obstacle, especially in places where STI testing funding is scarce. Moreover, the out-of-pocket expenses can also discourage people from getting tested on a regular basis, especially for populations without insurance or in areas without public healthcare systems.
Integration of telemedicine and digital health
The increasing use of telemedicine platforms and digital health solutions is opening up new avenues for CT/NG testing. People can easily and discreetly access STI services with at-home testing kits and app-based consultations. These platforms can support electronic prescriptions for treatment, remote result delivery, and instructions for sample collection. Better data collection and contact tracing are also made possible by digital health tools, which support public health surveillance. Additionally, diagnostic companies have a long-term opportunity to bundle testing with digital support services, as the COVID-19 pandemic has accelerated this trend and demonstrated that both patients and providers are growing more at ease with virtual care.
Competition in low-resource environments from syndromic management
Due to a lack of funding and access to laboratory testing, syndromic management of STIs is still widely used in many developing nations. This method reduces the need for diagnostics by treating symptoms without the need for confirmatory testing, despite being less accurate. The continued use of syndromic management jeopardizes CT/NG testing's ability to expand, particularly in public health systems where cost is a key consideration. Furthermore, diagnostic adoption may remain restricted in high-burden nations where it is most needed unless point-of-care tests become more accessible and incorporated into current procedures.
The COVID-19 pandemic had a mixed effect on the CT/NG testing market. At first, it caused testing services to be disrupted because of supply chain disruptions, the overburden on the healthcare system, and the reallocation of laboratory resources to SARS-CoV-2 diagnostics. As a result of the suspension or reduction of routine screening programs for STIs, such as gonorrhea and chlamydia, in many areas, testing volumes temporarily decreased and diagnoses were delayed. The pandemic did, however, also hasten the uptake of point-of-care diagnostics, telemedicine, and self-collection kits, establishing the foundation for more accessible and decentralized STI testing.
The assays & kits segment is expected to be the largest during the forecast period
The assays & kits segment is expected to account for the largest market share during the forecast period. The extensive use of molecular diagnostic tests, like nucleic acid amplification tests (NAATs), which are very sensitive and specific for identifying CT/NG infections, is what is causing this dominance. Because of their simplicity of use, quick turnaround times, and compatibility with automated platforms, these assays are frequently utilized in clinical laboratories, hospitals, and even at-home testing kits. Moreover, assay-based solutions have become increasingly popular due to the increasing need for early and precise diagnosis, particularly in asymptomatic individuals. As a result, this market segment now accounts for the largest portion of market revenue.
The home care settings segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the home care settings segment is predicted to witness the highest growth rate. The primary drivers of this growth are the growing demands for STI screening that are accessible, convenient, and private. Telehealth-based diagnostic services and at-home sample collection kits have become increasingly popular, especially since the COVID-19 pandemic changed patient preferences. By enabling people to send samples to accredited labs and perform self-tests without having to visit medical facilities, these solutions improve testing frequency and lessen stigma. Additionally, self-testing's ease of use, growing awareness, and technological developments are anticipated to greatly speed up this market's growth.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, mainly due to the region's population size, rising STI rates, and growing sexual health consciousness. Furthermore, the region's market dominance is largely due to growing access to advanced diagnostic technologies in nations like China, India, Japan, and Australia, as well as expanding healthcare infrastructure and government initiatives supporting STI screening programs. The market in Asia-Pacific is expanding due to the growing use of point-of-care testing kits and nucleic acid amplification tests (NAATs), which has made the region the world's most prominent location for CT/NG testing.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, motivated by a robust healthcare system, a high level of knowledge about STDs, and the broad use of cutting-edge diagnostic tools. Strong reimbursement practices, expanding screening initiatives and continuous R&D efforts all contribute to the market's expansion. Additionally, variables supporting the strong growth of the CT/NG testing market in North America include the availability of highly sensitive and quick testing techniques, as well as rising public and private investments in sexual health programs.
Key players in the market
Some of the key players in CT/NG Testing Market include Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Binx Health, Inc., Abbott Laboratories, Hologic Inc., Siemens Healthineers AG, ELITech Group SAS, Danaher Corporation, Seegene, Inc., Genetic Signatures Ltd., Becton, Dickinson and Company (BD), Qiagen N.V., Meridian Bioscience Inc. and PerkinElmer Inc.
In February 2025, Bio-Rad Laboratories, Inc launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The new kits are designed to offer a convenient method to label any antibody with one of Bio-Rad's StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments. The new two-kit system provides researchers access to Bio-Rad's StarBright Blue and StarBright Violet Dyes, employing Bio-Rad's SpyTag and SpyCatcher technology to conjugate a dye to an antibody of choice.
In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.
In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida's R&D portfolio includes pre-clinical and clinical-stage off-the-shelf CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.